Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05837689

Minimal Residual Disease Quantification by Next-generation Sequencing in Pediatric B-ALL Children Patients Treated With Blinatumomab Consolidation

Acute Lymphoblastic Leukemia, Pediatric Clinical Trial

Official title:
Minimal Residual Disease Quantification by Next-generation Sequencing in Pediatric B-ALL Children Patients Treated With Blinatumomab Consolidation

Clinical Trial Summary

A retrospective analysis to investigate pediatric B-cell acute lymphoblastic leukemia patients who were treated with blinatumomab for consolidation, and who were detected as minimal residual disease (MRD) positive by next generation sequencing (NGS). The efficacy of blinatumomab clearing MRD detected by NGS will be analyzed, in order to see the potential of using NGS to guide MRD eradication by blinatumomab.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Acute Lymphoblastic Leukemia, Pediatric
  • Neoplasm, Residual
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
Clinical Trial Details
NCT number NCT05837689
Study type Observational
Source The Children's Hospital of Zhejiang University School of Medicine
Contact
Status Not yet recruiting
Phase
Start date April 2023
Completion date April 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03676504 - Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR Phase 1/Phase 2
Enrolling by invitation NCT05622682 - Vaccine Immune Recovery After Leukemia
Not yet recruiting NCT05029531 - Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021) Phase 3
Not yet recruiting NCT06107478 - Parental Perception of Their Child's Emotional Quality of Life in Paediatric Oncology Before and After "Magic Massages"
Recruiting NCT05809284 - Determining the Mechanisms of Loss of CAR T Cell Persistence
Recruiting NCT04049383 - CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL Phase 1
Active, not recruiting NCT04472286 - Healthy Bones, Healthy Life: Habitual Physical Activity on Bone & Metabolic Health in Pediatric Cancer Survivors
Completed NCT05973032 - MRD Detection by NGS in Pediatric B-ALL
Completed NCT05032716 - EFFECT OF TREADMILL TRAINING ON BALANCE AFTER CHEMOTHERAPY IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA N/A
Recruiting NCT03035344 - Study of the Intermediate Metabolism in Children With Acute Lymphoblastic Leukemia (ALL) N/A
Terminated NCT03705507 - International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia Phase 1/Phase 2
Recruiting NCT04325841 - Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children Phase 2
Active, not recruiting NCT03020030 - Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents Phase 3
Not yet recruiting NCT06257394 - Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea Phase 2
Active, not recruiting NCT03157323 - Low GI Diet in Children and Adolescents With ALL N/A
Recruiting NCT04996160 - Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2) Phase 1
Not yet recruiting NCT06421155 - Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia N/A
Recruiting NCT03643276 - Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 Phase 3
Recruiting NCT06074666 - Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Study 3 N/A
Active, not recruiting NCT04088864 - CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies Phase 1